Essential Partners’s Alto Neuroscience ANRO Stock Holding History

Essential Partners’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8	Closed	-$18	–	2803
2025 Q2	$18	Buy	+8	New	+$19	﹤0.01%	2231

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Essential Partners's ANRO Position: Q3 2025 in Review

Essential Partners sold out of Alto Neuroscience (ANRO) in Q3 2025, closing a stake of 8 shares — an estimated $18 sold.

Essential Partners first reported a position in ANRO in Q2 2025 and held it in 1 quarter. The position peaked at $18 in Q2 2025. 77 funds tracked by Wall St. Rank hold ANRO as of Q3 2025.

Essential Partners reported no remaining Alto Neuroscience position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 8 Alto Neuroscience shares in Q3 2025, an estimated $18.
Essential Partners first reported a position in Alto Neuroscience in Q2 2025 and held it in 1 quarter.
Essential Partners's Alto Neuroscience position peaked at $18 in Q2 2025.
77 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.